Cécile Fortuny

Cécile Fortuny has a diverse work experience in the field of scientific research. Cécile started their career as an Undergraduate Research Assistant at the Centre européen d'étude du Diabète (CeeD), where they contributed to exploring therapeutic alternatives to insulin injections. Cécile then joined the Helen Wills Neuroscience Institute at UC Berkeley as a Junior Specialist before pursuing their PhD in Vision Science at the University of California, Berkeley. During their PhD, Cécile focused on gene therapy for inherited retinal diseases, specifically using Adeno-Associated Viruses (AAV) to develop novel treatments. After completing their PhD, they interned at Genentech as a PhD Intern. Following this, Cécile worked as a Postdoctoral Researcher at the Helen Wills Neuroscience Institute, where they continued their research in neuroscience. Most recently, they joined Scribe Therapeutics as a Scientist, where they are currently involved in scientific research.

Cécile Fortuny began their education in 2007 at IUT de Schiltigheim, Université de Strasbourg, where they obtained an Associate of Science (AS) degree in Biotechnology in 2009. Cécile then enrolled at the University of Strasbourg from 2009 to 2010 and received a Bachelor of Science (BS) degree in Cell biology and Physiology. Continuing their studies, they pursued a Master of Science (MS) degree in Pharmacology at the University of Strasbourg from 2010 to 2012. Finally, Cécile Fortuny attended the University of California, Berkeley, from 2013 to 2019, where they completed their PhD in Vision Science/Neuroscience.